FIGURE 3 HERE
Figure 3. Pathways identified that support montelukast repurposing. A. Molecular basis of Alzheimer’s disease. Amyloid precursor protein (APP) can be processed through a non-amyloidogenic pathway, where it is cleaved by α- and γ-secretases, or through an amyloidogenic pathway, where it is cleaved by β- and γ-secretases, leading to the formation of Aβ peptides (Chenet al. , 2017; De Strooper et al. , 2010). Aβ peptides can then undergo clearance (or degradation) processes within the brain or after transport from the brain to the periphery (liver and kidney). These processes include proteolytic pathways that depend on neprilysin (NE), insulin-degrading enzyme (IDE), matrix metalloproteinases (MMPs), angiotensin-converting enzyme (ACE), endothelin-converting enzyme (ECE), plasmin, the activity of the ubiquitin-proteosome system, the autophagy-lysosome system, or microglial phagocytosis (Nalivaeva and Turner, 2019; Xin et al. , 2018). Image adapted from Marqueset al. (2022c). B. Energy producing glycolytic pathway and tricarboxylic acid cycle (Yan et al. , 2020). Enzymes marked in red represent the MTK-altered proteins. Created with BioRender.com.